DJIA 17,213.75 56.90 0.33%
NASDAQ 4,581.53 19.34 0.42%
S&P 500 2,007.65 6.08 0.30%
market minute promo

Johnson & Johnson (NYSE: JNJ)



company name or ticker
Company Photos
(Click to zoom)

Gilead Sciences, inc. Stock's Incoming Game Changer

Gilead's Sovaldi sales could reach $10 billion this year, but sales could head even higher next year if the FDA approves its Sovaldi and ledipasvir combination drug.

Don't Own A Company If You Wouldn't Display It On Your Wall

3 Hot Ways to Play the Biotechnology Bonanza

New Active ETF for All Risk Environments

Actavis Is The Best Bet In The Drug Sector

Why It's Time for Allergan Shareholders to Take Some Profits

Buy The Dip In Gilead: Why A Decrease In Quarterly Sovaldi Revenue Is Expected

Is There Further Upside In Medivation?

Lawyer grills DePuy executive over safety studies for Pinnacle hips

3 Stocks Reiterated As A Buy: MA, NTAP, JNJ

See More Articles...